Skip to main content

Biocept's Immuno-Oncology PD-L1 Test

Biocept has launched its first test for use in guiding cancer immunotherapies, a PD-L1 protein expression assay performed on circulating tumor cells. The CLIA-validated test, developed by Biocept scientists in collaboration with Yale University School of Medicine's David Rimm, is intended to be used to detect and monitor PD-L1 protein expression throughout the course of a patient's treatment with newly approved immuno-oncologic drugs.  

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.